AR and Sepsis: Whilst understanding the outcome of receptor-specific AR signalling on immune cell function is beneficial for the development of therapeutics to modulate SNS signalling in sepsis, it remains unlikely that a single AR pathway is activated in immune cells in vivo, given their expression of multiple AR subtypes and the promiscuous binding of endogenous catecholamines to all AR subtypes.